Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors during the central nervous method, conolidine modulates alternate molecular targets. A Science Advances research found that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://michaell097gxi9.pennywiki.com/user